The study provides novel mechanistic insights into the design and activity of CEA TCB, an
Introduction
Redirecting the activity of T cells by bispecific antibodies against tumor cells, independently of their TCR specificity, is a potent approach to treat cancer (reviewed in (1-3)). The concept is based on recognition of a cell surface tumor antigen and simultaneous binding to the CD3 epsilon chain (CD3e) within the T cell receptor (TCR) complex on T cells. This triggers T cell activation, including release of cytotoxic molecules, cytokines and chemokines and induction of T cell proliferation (1, 2).
The first T cell bispecific antibody was described 30 years ago (4), but it was only recently that the first TCB for systemic administration to cancer patients, blinatumomab, an anti-CD19 × anti-CD3e TCB, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory B cell acute lymphocytic leukemia (B-ALL) (5) . A major limitation of the earlier TCB molecules was that they induced strong cytokine release and resulted in severe infusion related reactions, which precluded their systemic administration.
Indeed such an earlier TCB, catumaxomab, targeting EpCAM, could only be applied for local, peritoneal administration for the treatment of malignant ascites (6) . Besides being highly immunogenic in humans (as rat/mouse hybrid monoclonal antibody), catumaxomab carries an active Fc domain capable of crosslinking FcγRs on innate immune cells and CD3e on T cells, which leads to strong cytokine release upon systemic administration, independently of tumor target cell binding (7) . This limitation was overcome in blinatumomab by removing the Fc domain and linking the anti-CD19 and anti-CD3e domains via a short, flexible Gly-Ser linker (3) . However, by removing the Fc region, protection from catabolism via FcRn recycling was eliminated and this, together with the small molecular size of blinatumomab, leads to fast drug clearance. Indeed, blinatumomab has to be administered via continuous infusion for several weeks (5) , an approach which would significantly limit the application of Author Manuscript Published OnlineFirst on February 9, 2016; DOI: 10.1158/1078-0432.CCR- TCBs to the majority of cancer patients. Thus new TCB molecular formats with comparable or higher efficacy than blinatumomab, but with significantly longer circulatory half-life allowing for systemic administration every few weeks and at the same time avoiding peripheral immune cell activation and cytokine release in the absence to target engagement, are desired.
Another obstacle to the broad utilization of TCBs is the availability of suitable, tumorspecific targets. Most solid tumor targets are overexpressed on tumor cells but expressed at lower, yet significant levels on non-malignant primary cells in critical tissues. In nature, T cells can distinguish between high and low antigen expressing cells by means of relatively low affinity TCRs that can still achieve high avidity binding to target cells expressing sufficiently high levels of target antigen. Molecular TCB formats that could accomplish the same, and thus maximize the window between killing of high-and low-target expressing cells, would be highly desirable.
The current manuscript highlights the novel molecular features of CEA TCB (RG7802; RO6958688; Fig.1A ), which is the only IgG-based CEA T cell bispecific antibody that entered clinical trials to date ((8) , NCT02324257) and is differentiated from previouslydescribed scFv or diabody-based T cell bispecific antibodies targeting CEA. CEA, also called carcinoembryonic antigen related cell adhesion molecule 5 (CEACAM5) or CD66e, is a 180-200 kDa protein that belongs to the CEACAM superfamily and is anchored to the cell surface via glycosylphosphatidylinositol (GPI). CEA expression in various tumor entities is generally very high, especially in colorectal carcinoma (CRC), pancreatic adenocarcinoma (PanCa), gastric cancer (GC), non-small cell lung cancer adenocarcinoma (NSCLC), breast cancer (BC), head and neck carcinoma (HNSCC), uterine and bladder cancers amongst others (9) .
Low expression is found in small cell lung cancer and glioblastoma (10) (11) (12) (13) (14) (15) . CEA is expressed at low levels on the apical surface of glandular epithelia in the gastrointestinal (GI) tract, but its polarized expression pattern limits accessibility to therapeutic antibodies administered systemically (10, 11, 16, 17) . In addition to the novel molecular features of the TCB format, the manuscript provides insights into interesting aspects related to the biological activity of CEA TCB, including a threshold of CEA receptors required for activity, selectivity for high CEA-expressing tumor cells, efficacy in non-inflamed and poorly T cell-infiltrated tumors and the ability to increase T cell infiltration in tumors thus generating a more inflamed tumor microenvironment.
Research. 
Materials and Methods
Cells, CEA expression level and antibody binding. The list of all cell lines used in the study, their source and authentication is provided in Table S1. The cell line panel (C10, C106,   C10A, C10S, C125PM, C2BBe1, C32, C70, C75, C80, C99, CACO2, CAR1, CC20, CCK81,   CCO7, CL11, CL14, CL40, COCM1, COLO201, COLO205, COLO206, COLO320DM,   COLO320HSR, COLO678, CW2, CX1, DLD1, GP2d, GP5d, HCA46, HCA7, HCC2998,   HCC56, HCT116, HCT15, HDC111, HDC114, HDC135, HDC142, HDC143, HDC54,   HDC57, HDC73, HDC8, HDC82, HDC9, HRA19, HT29, HT55, ISRECO1, JHCOLOYI,   JHSK-rec, KM20L2, LIM1215, LIM1863, LIM2405, LOVO, LS1034, LS123, LS174T,   LS180, LS411, LS513, NCIH508, NCIH548, NCIH716, NCIH747, OUMS23, OXCO1,   OXCO2, OXCO3, PCJW, PMFKO14, RCM1, RKO, RW2982, RW7213, SKCO1, SNU1181,   SNU1235, SNU1411, SNU1544, SNU1684, SNU1746, SNU254, SNU479, SNU70, SNU977,   SNUC1, SNUC2B, SW1116, SW1222, SW1417, SW1463, SW403, SW48, SW480, SW620,   SW837, SW948, T84, TT1TKB, VACO10MS, VACO429, VACO4A, VACO4S, VACO5 and WIDR) has been accumulated over a period of more than 25 years and, in many cases, cell lines were obtained from their originators before they became available from commercial cell banks. C10, C106, C125PM, C32, C70, C75, C80 and C99 cell lines have been (Table S1 ). 19 cell lines were also screened using the (Table S1 ). The cell line panel mentioned above has also been characterized for RER status and for driver mutations in following genes: APC, TP53, CTNNB1, KRAS, BRAF, PIK3CA and FBXW7. All cell lines were obtained more than 6 months before the start of the experiments described in this paper and all were tested regularly for absence of mycoplasma using the MycoAlert™ Mycoplasma Detection Kit (Lonza). Histological Analysis. Tumor tissues from termination animals were fixed in 4% PFA (Paraformaldehyde) overnight and embedded in paraffin. Briefly, 4 μm Sections were cut using a Microtome (Leica) and mounted on glass slides. Samples were de-paraffinized and heat antigen retrieval was performed prior to immune-staining for human CEA (Roche), human CD3 (Abcam), human CD45 (Ventana), human CD8 (Abcam) and human PD-L1 (Ventana). The sections were counterstained with hematoxylin (Sigma Aldrich) and slides scanned using Olympus VS120-L100.
Assessment

Results
Structural characteristics and binding properties of CEA TCB. CEA TCB is an IgG1-based bispecific heterodimeric antibody that binds with one arm to CD3epsilon chain (CD3e) expressed on T cells and with two arms to CEA expressed on tumor cells (Fig. 1A) . The correct association of light chains of the antibody is enabled by introducing a CH1-CL crossover into the internal CD3 binding Fab (18) , whereas correct heavy chain association is facilitated via the knob-into-hole technology (19, 20) . CEA TCB binds to human CEAexpressing tumor cells bivalently with avidity of 10 nM (Fig.1B) , and targets a membraneproximal domain of human CEA (21, 22) . The CEA binder used in CEA TCB (named CH1A1A) is a humanized, affinity matured and stability-engineered version derived from the PR1A3 antibody (23, 24) . As the membrane-proximal domain of CEA is not conserved among species, CEA TCB binds specifically to human CEA and does not cross-react with Cynomolgus monkey CEA (Fig.S1 A) . In addition, CEA is not expressed in rodents so CEA (Fig.2 A) , and formation of the immunological synapses, as observed by imaging of talin clustering, MTOC re-localization and perforin re-distribution at the interface between tumor cells and T cells (Fig.2 B-C) . T cell activation (CD8>CD4) is further reflected by the expression of activation markers detected as early as 8.5 h post addition of CEA TCB to co-cultures of CEA-expressing tumor cells and human PBMCs (Fig.2 D -E) , finally leading to time-and dose-dependent lysis of tumor cells (Fig.2 F) . As further hallmark of T cell activation upon tumor lysis, a number of cytokines were detected in culture supernatants, including interferon gamma (IFNg), tumor necrosis factor (TNF), interleukin (IL)-2, IL-6, IL-10 as well as cytotoxic granule granzyme B (Fig.2 G) . Following CEA TCB-mediated tumor lysis, both CD8 and CD4 T cell subsets undergo dose-dependent proliferation ( (Fig. 3 A) . To further corroborate the initial findings, CEA TCB activity was assessed on a panel of 110 colorectal cancer cell lines (CRC) expressing various levels of surface CEA (Table S1) pattern of CEA expression. In general, there were two major groups of target cells displaying < 10% (non-responders, red squares) and > 10 % (responders, blue squares) of tumor lysis (Fig. 3 B) . When looking at CEA expression, we noticed that the non-responder group had predominantly (with only few exceptions) < 10 000 CEA binding sites, whereas the cell lines belonging to the responder group were characterized by > 10 000 CEA binding sites (Fig. 3 B and C). A comparison of the CEA expression level between the two groups showed statistically highly significant difference in CEA expression (Fig. 3 C, ****p<0.0001), suggesting a strong and robust correlation between CEA expression level on target cells and CEA TCB activity. Interestingly, the tests performed to look for associations between the major genetic changes found in colorectal carcinomas and the response to CEA TCB therapy, including correlations with the replication error (RER) status and mutations in APC, TP53, CTNNB1, KRAS, BRAF, PIK3CA and FBXW7, did not result in any significant correlation (Table S2) , further suggesting that, based on in vitro data, CEA expression level appears to be the strongest predictor of CEA TCB activity.
In vivo activity of CEA TCB. The anti-tumor activity of CEA TCB was initially assessed using a human colon carcinoma xenograft model (LS174T) stably expressing firefly luciferase (LS174T-fluc2), co-grafted with human PBMCs at E:T ratios of 5:1 and 1:1 (Fig. 4 A-D). Mixed cells were injected s.c. in immunodeficient NOG mice. Treatment schedules of CEA TCB were selected based on single-dose PK profile (SDPK) of i.v. bolus injection of CEA TCB in NOG mice (Fig.S2 A-C) . CEA TCB, untargeted TCB (both given at 2.5 mg/kg) or vehicle (PBS) were administered twice/week starting either one day or seven days post tumor/PBMC co-grafting (red arrow). CEA TCB mediated strong tumor growth inhibition when administered either one day or seven days after tumor/PBMC co-grafting at both E:T ratios (E:T 5:1, Fig. 4 A, B and E:T 1:1 Fig. 4 C, D) . On the contrary, in control groups (treated with PBS (vehicle) or untargeted TCB) tumors continued growing (Fig. 4 A-D) .
CEA TCB activity was further monitored by live imaging using intravital two-photon (2P) microscopy (Fig. 4 E) (Fig. 4 E) . Together, the tumor growth inhibition and two-photon imaging data generated in preclinical mouse tumor models revealed that CEA TCB displays potent anti-tumor activity independently of the baseline immune cell infiltration. The staining of the same tumors with anti-PD-L1 antibody demonstrated an induction of intra-tumor PD-L1 expression upon CEA TCB treatment as compared to control (Fig. 5 F) . CrossMAb and knob-into-hole technologies (18, 33) . The bivalency for the tumor antigen confers high binding avidity to the tumor and translates into better tumor targeting and retention as compared to antibodies having monovalent binding to CEA (Fig. S3 A-E) ; it also allows a better differentiation between high and low CEA-expressing tumor cells (Fig. 3) . (Table S1 and Fig. 3 A) . Interestingly, the correlation performed to assess any association between the major genetic changes described in colorectal cancer and the response to CEA TCB therapy, including correlations with the replication error (RER) status, mutations in APC, TP53, CTNNB1, KRAS, BRAF, PIK3CA and FBXW7, did not result in any significant correlation further suggesting that, based on in vitro data, CEA expression level appears to be the strongest predictor of CEA TCB activity.
The high avidity binding to CEA conferred by the antibody's design, together with the bivalent binding mode to tumor antigen, translates into a selective killing of high CEAexpressing tumor cells and sparing of the normal epithelial cells. This finding, along with the knowledge that primary epithelial cells express low levels of CEA inaccessible to therapeutic antibodies (due to its polarized expression pattern facing glandular lumen (11, 34, 35) , provides confidence into a wide safety window of CEA TCB to select between primary and malignant cells. This is particularly relevant considering that there were no relevant pre- 
In addition to tumor cell killing, our study unravels novel elements related to the TCB mode of action and provides mechanistic insights into T cell/CD3 activation, formation of immunological synapses, T cell activation and proliferation (expansion) upon TCB trigger. 
Figure legends
